Last updated: February 15, 2026
What is NDC 65162-0807?
The National Drug Code (NDC) 65162-0807 corresponds to Selinexor (Xpovio), marketed by Karyopharm Therapeutics. This drug is an oral Selective Inhibitor of Nuclear Export (SINE) used primarily for treating relapsed or refractory multiple myeloma in adult patients.
Market Size and Demand
- Indication: Multiple myeloma, a malignant plasma cell disorder, has a global market estimated at $18 billion in 2022, with a compound annual growth rate (CAGR) of approximately 6-8% (EvaluatePharma, 2022).
- Patient Population: Approximately 32,000 new cases annually in the U.S., with around 150,000 living patients on therapy.
- Market Penetration: Selinexor entered as a second-line therapy in 2020, with its use expanding as a third-line and multi-therapeutic option.
- Competitors: Includes drugs like carfilzomib, daratumumab, and other proteasome inhibitors or monoclonal antibodies. The multiple myeloma market remains competitive, but Selinexor's unique mechanism offers niche advantages.
Revenue Forecasts
- Current Sales (2022-2023): Estimated at $350 million, driven by increasing adoption in refractory cases.
- Projected Growth: Market analysts forecast revenue reaching $650 million to $900 million by 2027, assuming expanded label indications and increased utilization.
Price Structure and Cost Factors
- Wholesale Acquisition Cost (WAC): Approximately $14,000 to $15,000 per month per patient, based on publicly available pharmacy data and wholesale pricing sources (Red Book, 2023).
- Average Selling Price (ASP): Likely lower than WAC due to discounts, rebates, and payer negotiations, estimated at $12,000 to $13,500 per month.
Pricing Comparisons
| Drug Name |
Monthly Cost (Average) |
Indicated Use |
Market Share |
| Selinexor (Xpovio) |
$12,000 – $13,500 |
Multiple myeloma (refractory) |
Growing in refractory cases |
| Carfilzomib (Kyprolis) |
$13,500 – $15,500 |
Relapsed multiple myeloma |
Established, competitive |
| Daratumumab (Darzalex) |
$10,000 – $16,000 |
Multiple myeloma |
Leading in first-line use |
Note: Prices are approximate and vary by payer, region, and negotiated agreements.
Price Projections and Factors
- Market Expansion: As more indications receive FDA approval, prices may stay stable or increase due to added therapeutic value.
- Generic Competition: No generics are currently available; patent exclusivity extends until at least 2030. Patent challenges or biosimilar development could influence future pricing.
- Pricing Trends: The oncology area has seen price stability with periodic adjustments driven by inflation, R&D costs, and market dynamics.
| Year |
Estimated Monthly Price |
Assumptions |
| 2023 |
$12,500 |
Current pricing with slight discounts |
| 2025 |
$12,000 – $13,500 |
Slight decrease due to payer pressure, stabilization |
| 2027 |
$11,500 – $13,000 |
Increased utilization and possible indication expansion |
Key Factors Impacting Price Projections
- Regulatory Approvals: New indications can lead to increased demand, stabilizing or raising prices.
- Reimbursement Landscape: Value-based payment models and insurance negotiations will influence effective patient costs.
- Market Competition: The entrance of biosimilars or alternative modalities could put downward pressure on pricing.
Summary
Selinexor (NDC 65162-0807) is positioned within a high-growth niche of refractory multiple myeloma therapies. Its current U.S. wholesale price ranges between $12,000 and $13,500 monthly, with future prices likely to remain stable or slightly decline until patent expiration or significant market shifts. Revenue projections suggest considerable upside, contingent on indication expansion and competitive dynamics.
Key Takeaways
- The drug is a niche therapy with expanding use but faces limited near-term competition.
- Current price estimates are around $12,000 to $13,500 monthly WAC.
- Revenues forecast to reach up to $900 million annually by 2027.
- Price stability will depend on regulatory approvals, reimbursement policies, and market competition.
- Patent exclusivity runs until at least 2030, limiting generic impact.
FAQs
1. How is the price of Selinexor set?
The price is determined by manufacturer pricing strategies, R&D costs, negotiated rebates, and payer agreements. WAC estimates serve as basis points for broader market pricing.
2. What factors could lower the drug's price in the future?
Introduction of biosimilars, patent challenges, increased competition, and policy changes favoring value-based pricing could reduce prices.
3. How does Selinexor compare to other multiple myeloma drugs?
It has a unique mechanism, making it suitable for refractory cases. Its cost is similar to other second-line therapies, with some variance based on payer negotiations.
4. What is the expected impact of new indications on pricing?
New approvals typically lead to increased demand, potentially stabilizing or increasing prices depending on market acceptance and payer coverage.
5. Are there upcoming patent protections or exclusivities?
Yes, patents typically extend until at least 2030. Challenges from biosimilars or legal disputes could alter this timeline.
Sources
- EvaluatePharma. (2022). Oncology Market Data.
- Red Book. (2023). Drug Price & Market Data.
- U.S. FDA. (2022). Approved Drug Label for Selinexor.
- IQVIA. (2023). Market Dynamics in Oncology.
[1] – EvaluatePharma, 2022
[2] – Red Book, 2023
[3] – FDA, 2022
[4] – IQVIA, 2023
